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■ Abstract
Background: Serum chitinase-like proteins such as YKL-40 in asthmatic patients are known to positively correlate with disease severity 
but controversy remains regarding their role. The allergen bronchial provocation test (ABPT) can induce allergic airway inﬂ ammation in 
individuals with atopic asthma.
Objective: To evaluate the induction and kinetics of YKL-40 during allergen-induced airway inﬂ ammation in atopic asthmatics.
Methods: Thirteen patients were enrolled from May to November 2008. They all underwent ABPT with Dermatophagoides farinae crude 
extract. Induced sputums (IS) and serum were collected 3 times: 7 days before ABPT (baseline), 7 hours after ABPT, and 24 hours after 
ABPT. We examined the cytology of induced sputum (IS) and measured levels of YKL-40, interleukin (IL) 4, IL-5, IL-13, IL-33, tumor necrosis 
factor (TNF) _, and eosinophilic cationic protein (ECP) in IS and/or serum.
Results: Following ABPT, total inﬂ ammatory cells, eosinophils, and neutrophils increased in a time-dependent manner in IS. YKL-40 levels 
were increased in IS but not in serum at 7 or 24 hours after ABPT (P=.011 and P=.006, respectively). Similarly to YKL-40, IL-5 and ECP 
levels were also increased in IS at 7 and 24 hours after ABPT (P=.011 for IL-5 and P=.006 for ECP). Overall, YKL-40 levels were well 
correlated with ECP levels in IS (l=0.576, P<.001).
Conclusions: YKL-40 levels increased immediately in IS but not in the serum of atopic asthmatics. The correlation between YKL-40 levels 
and ECP in IS suggests that YKL-40 may play a pathophysiologic role in human atopic asthma. 
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■ Resumen
Antecedentes y objetivo: Las proteinas séricas "chitinase-like" como YKL-40 podrían correlacionarse en pacienes asmáticos con la severidad 
de la enfermedad. El objetivo de este estudio es evaluar la producción de YKL-40 y su cinética tras la provocación bronquial con alérgeno 
(PBA), una prueba que induce una potente respuesta inﬂ amatoria en sujetos afectos de asma bronquial alérgica.
Metodos: Se incluyeron en el estudio un total de 13 pacientes asmáticos en un periodo comprendido entre mayo y noviembre del 2008. 
a todos ellos se les realizá la PBA utilizando un extracto de Dermatophagoides farinae. Se obtuvieron muestras de suero y de esputo 
inducido (EI) en tres ocasiones — 7 días antes de la PBA (situación basal), y 7 y 24 horas tras la PBA. Se realizó un análisis citológico de 
las muestras de EI, y en el sobrenadante se cuantiﬁ caron los niveles de YKL-40, interleuquina 4 (IL) 4, IL-5, IL-13, IL-33, factor de necrosis 
tumoral (TNF) _, y de la proteina catiónica del eosinóﬁ lo (ECP). Estas determinaciones también se realizaron en las muestras de suero.
Resultados: tras la PBA se observó un incremento marcado en función del tiempo en el total de células inﬂ amatorias, eosinóﬁ los y 
neutróﬁ los en las muestras de EI. Los niveles de YKL-40 también se incrementaron en el EI a las 7 y 24 horas de la PBA (p=0,011 y 
p=0.006, respectivamente), mientras que no se modiﬁ caron los niveles séricos. Los niveles de IL-5 y ECP en EI también se incrementaron 
signiﬁ cativamente (p=0,011 para la IL-5 y p=0,006 para la ECP) tanto a las 7 como a las 24 horas de la PBA. Se constató una correlación 
entre los niveles YKL-40 y ECP en EI (l=0,576, p<0,001).
Conclusiones: Los niveles de YKL-40 se incrementas de forma inmediata tras la provocación en EI de pacientes asmáticos alérgicos, y no así 
en el suero. La correlación presente entre los niveles de ECP e YKL-40 en esputo, sugeriría un posible papel deYKL-40 en la ﬁ siopatológía 
del asma alérgica. 
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Introduction
YKL-40, also called human cartilage glycoprotein 39 (HcGP-
39), is a chitinase-like protein that was À rst discovered in synovial 
Á uid; its murine homolog is known as BRP-39 [1,2]. YKL-40 is 
known to be associated with a number of human inÁ ammatory 
diseases, such as rheumatoid arthritis [3], osteoarthritis [4], 
sarcoidosis [5], inflammatory bowel disease [6], hepatic 
À brosis [7], and several malignant tumors [8]. YKL-40 levels 
were recently shown to be related to endocrine diseases 
including obesity [9], diabetes mellitus, and atherosclerosis [10]. 
In addition, elevated YKL-40 levels have been reported in 
the serum, sputum [11], and bronchoalveolar lavage (BAL) 
Á uid [12] of patients with chronic obstructive pulmonary 
disease (COPD). The relationship between YKL-40 and 
various human diseases suggests that this protein could be a 
useful diagnostic and prognostic biomarker. 
The activation of type 2 helper (TH2) lymphocytes and 
their subsequent secretion of interleukin (IL) 13 are well-
established key responses in the pathogenesis of allergic airway 
inÁ ammation [13]. Induction of IL-13 secretion results in 
the alternative activation of alveolar macrophages, and these 
activated macrophages have been reported to play a role in the 
propagation of inÁ ammation [14]. Respiratory epithelial cells, 
alveolar macrophages, and neutrophils are known to secrete 
YKL-40 in human airways, and hence, YKL-40 has been 
attributed a role in airway inÁ ammation [15]. Furthermore, an 
animal model study has shown that YKL-40 may play a critical 
role in various steps of asthma pathogenesis by increasing 
allergic sensitization, propagating TH2 inÁ ammation, and 
regulating inÁ ammatory cell apoptosis [16]. 
In this study, we evaluated dynamic changes in YKL-40 levels 
in induced sputum (IS) following an allergen bronchial provocation 
test (ABPT) with house dust mite extract (Dermatophagoides 
farinae [DF]) in the hope that our À ndings would shed light on 
the mechanisms underlying atopic asthma [17].
502
Methods
Patients
Thirteen patients who visited Severance Hospital to have 
their allergic asthma presumptively diagnosed by a physician 
were enrolled between May and November 2008. The 
Institutional Review Board of Yonsei University approved 
the study (IRB no. 4-2012-0002) and informed consent 
was obtained from all patients. According to international 
guidelines [18], the diagnosis of allergic asthma was based 
on clinical history, symptoms and signs, the methacholine 
bronchial provocation test, eosinophil count in IS, and speciÀ c 
immunoglobulin (Ig) E measurements by skin prick testing 
(Allergopharma) and/or the ImmunoCAP test (Pharmacia). DF-
speciÀ c IgE was documented in all patients. All participants 
underwent ABPT with DF extract. IS and serum were collected 
3 times: 7 days before ABPT (baseline) and at 7 and 24 hours 
after the À rst dose of allergen administration (Table 1). 
Allergen Bronchial Provocation Test
DF whole body extract (1:100 w/v, containing 3.4 +g/mL of 
Der f 1) cultured at the Institute of Allergy, Yonsei University 
was used for ABPT. To prepare the inhalation material, a 1:100 
extract of DF in phosphate buffered saline (PBS) was À ltered 
with an antiseptic À lter (Millipore) and diluted 10-, 25-, and 
100-fold with isotonic saline. A baseline pulmonary function 
test was performed using a pneumotachometer system with a 
Lilly head (MasterScreen system, Erich Jaeger Co.), which 
measures maximum expiratory Á ow volume. The spirometric 
Á ow-volume curve was obtained according to international 
criteria [19].
ABPT was performed using the method described 
by Spector et al [20], with some modiÀ cations. First, DF 
solution (1:10 000 w/v) containing 34 ng/mL of Der f 1 
was administered using a handheld nebulizer (Devilbiss 
Table 1. Demographic and Laboratory Data of Patients Included in the Study 
  No. Sex Age, y Diagnosis Treatment Smoking, PC
20
, mg/mL DF sIgE DF SPT, mm
      pack-years  kU/L  
    1 M 19 BA LTRA Never 2.43 18.7 8.0
 2 M 21 BA, AR None 0.2 8.31 31.5 32.0
 3 M 22 BA None Never 5.0 11.2 11.0
 4 M 19 BA, AR, AD None Never 0.84 >100.0 8.5
 5 M 19 BA ICS/LABA Never 10.0 14.3 7.5
 6 M 19 BA None Never 0.12 25.4 7.0
 7 M 20 BA, AR None Never 3.15 38.7 30.5
 8 M 20 BA None 1.0 0.28 2.38 5.0
 9 M 19 BA, AR, AD ICS/LABA Never 1.25 5.53 6.5
 10 M 19 BA, AR, AD ICS/LABA Never 7.94 26.2 ND
 11 M 18 BA ICS/LABA Never 1.30 54.3 12.0
 12 M 18 BA None Never 1.25 53.2 ND
 13 M 20 BA ICS/LABA Never 7.64 1.72 ND
Abbreviations: AD, atopic dermatitis; AR, allergic rhinitis; BA, bronchial asthma; DF, Dermatophagoides farinae; ICS, inhaled corticosteroid; LABA, long-
acting ß2-agonist; LTRA, leukotriene receptor antagonist; ND, not done; PC20, methacholine provocation concentration for 20% decrease in forced 
expiratory volume in the ﬁ rst second; sIgE, speciﬁ c immunoglobulin E; SPT, skin prick test. 
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646, Devilbiss Healthcare Inc.) with tidal breathing for 2 
minutes. After administration, spirometric data including 
forced expiratory volume in the À rst second (FEV1) were 
obtained. A positive test was deÀ ned as a 20% decrease in 
FEV1 from baseline. If a negative result was observed, the next 
concentration was administered up to 1:1000 diluents. After the 
À nal dose was administered for 2 minutes, serial spirometry 
was performed at 10, 20, and 30 minutes and at 1, 2, 4, 5, 6, 
and 7 hours. A signiÀ cant decrease in FEV1 60 minutes after 
the À nal DF inhalation was deÀ ned as an early response, while 
a signiÀ cant decrease after 4 hours was deÀ ned an isolated 
late response. If both early and late responses were observed, 
a dual response was recorded. Patients who did not show any 
signiÀ cant spirometric changes after 7 hours of spirometric 
monitoring were considered nonresponders.
Induced Sputum Analysis
We used a previously reported method for sputum 
induction [21] with some modiÀ cations for processing [22]. 
Briefly, we checked each patient’s peak flow rate (PFR) 
with a mini-Wright peak Á ow meter. After administration of 
bronchodilator (salbutamol 200 +g, 2 puffs), sputum induction 
was performed with 3% hypertonic saline inhalation for 
10 minutes. PFR was checked again if the patient complained of 
dyspnea. Sputum induction was stopped when a 20% decrease in 
PFR from baseline was observed. To prevent contamination with 
squamous epithelial cells, sputum expectoration and collection 
were performed after cleaning of the oral and nasal cavities. 
Induced sputum samples were processed immediately 
as follows. Mucus components were collected separately 
from saliva, and the weight and volume of selected samples 
Eosinophil cationic protein (ECP) was also measured in IS with 
the commercially available ImmunoCAP assay (Phadia). The 
levels of other inÁ ammatory cytokines, including interleukin 
(IL) 4 (detection limit, 10 pg/mL), IL-5 (detection limit, 3.0 
pg/mL), IL-13 (detection limit,32 pg/mL), IL-33 (detection 
limit, 28 pg/mL), and tumor necrosis factor (TNF) _ (detection 
limit, 0.5 pg/mL) were also checked in IS and serum by ELISA 
(R&D Systems). 
Statistical Analysis
All data were analyzed using SPSS statistical software 
(version 12.0). The Wilcoxon test was used for comparing 
medians, and the Spearman rank test was used for correlation 
analysis. Data are presented using means (SD).
 
Results
Cytological Analysis of Induced Sputum
Total cell count increased in a time-dependent manner 
after ABPT (baseline, 384.7 [407.3] ×103 cells/mL; 7 hours, 
611.9 [593.1] ×103 cells/mL; 24 hours, 1160.5 [1232.8] ×103 
cells/mL). SigniÀ cant increases were also detected after this 
test for eosinophil count (baseline, 29.1 [49.4] ×103 cells/mL; 
7 hours, 157.9 [223.7] ×103 cells/mL; 24 hours, 546.0 [685.7] 
×103 cells/mL) and neutrophil count (baseline, 84.0 [81.9] ×103 
cells/mL; 7 hours, 247.2 [269.8] ×103 cells/mL; 24 hours, 381.4 
[658.5] ×103 cells/mL) (Figure 1). 
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Figure 1. Inﬂ ammatory cell counts in induced sputum. Total cell, neutrophil, and eosinophil counts 
increased signiﬁ cantly in a time-dependent manner after the allergen bronchial provocation 
test (ABPT). All data are represented by mean (SEM). *: P<.05 compared to baseline, #: P<.05 
compared to 7 hours after ABPT.
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measured. Then, an equal amount of 0.1% 
dithiothreitol (Sigma) was added to each 
mucus sample, vortexed for 15 seconds, and 
incubated in a warm water bath (37°C) with 
shaking for 20 minutes. The samples were 
centrifuged and the supernatant was collected 
for subsequent measurements and stored 
at ï70°C. Remnant cell components were 
resuspended in PBS and À ltered through a 
nylon mesh with 60-+m pores to eliminate 
cell clots. A 10-+L aliquot of resuspension 
solution was mixed with 10 +L of 0.4% trypan 
blue solution to count total cell numbers 
and measure cell viability using a Neubauer 
counting chamber. Samples were then diluted 
in PBS to a concentration of 1×106 cells/mL, 
and cytospin was performed at 450 rpm for 
6 minutes to prepare cytology slides. After 
staining the slides with Wright’s stain, over 400 
inÁ ammatory cells were counted differentially 
under a light microscope. 
Measurement of YKL-40, Eosinophil 
Cationic Protein, and Cytokines
YKL-40 levels were measured in IS and 
serum by enzyme-linked immunosorbent assay 
(ELISA) (Quidel) (detection limit, 20 ng/mL) [15]. 
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Figure 2. Enzyme-linked immunosorbent assay results of YKL-40, inﬂ ammatory cytokines, and eosinophil cationic protein (ECP) by immunoCAP in 
induced sputum (IS) and serum. YKL-40 (A), IL-5 (B), and ECP (D) levels increased signiﬁ cantly in a time-dependent manner in IS but not in serum after 
the allergen bronchial provocation test (ABPT). Interleukin (IL) 4 (C), IL-13 (E), IL-33 (F), and tumor necrosis factor (TNF) _ (G) levels were not changed 
in IS or serum. All data are represented as means (SEM). 
*P<.05 compared to baseline; #P<.05 compared to 7 hours after ABPT.
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Figure 3. Scatter plots of YKL-40 vs eosinophil cationic protein (ECP) (A) and eosinophil count (B) in induced sputum for all paired samples. Each plot 
shows a substantial positive correlation. Closed squares represent baseline, closed triangles represent 7 hours after the allergen bronchial provocation 
test (ABPT), and closed circles represent 24 hours after ABPT.
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Changes in YKL-40 Levels in IS and Serum After 
ABPT
YKL-40 levels in IS were increased signiÀ cantly at 7 and 
24 hours after ABPT (baseline, 18.7 [11.8] ng/mL; 7 hours, 
37.8 [29.7] ng/mL; 24 hours, 65.0 [52.9] ng/mL). However, 
there were no signiÀ cant differences in serum levels (baseline, 
53.0 [23.7] ng/mL; 7 hours, 53.1 [34.4] ng/mL; 24 hours, 55.9 
[30.6 ] ng/mL) (Figure 2A). 
Changes in Cytokine and ECP Levels in IS and Serum 
After ABPT
Only IL-5 levels were signiÀ cantly increased in IS at 24 
hours after ABPT (baseline, 6.6 [9.6] pg/mL; 7 hours, 12.1 
[13.1] pg/mL; 24 hours, 29.3 [24.7] pg/mL) (Figure 2B). IL-4 
was not detected in the samples and there were no signiÀ cant 
differences in IL-13, IL-33, or TNF-_ levels in either IS or 
serum (Figure 2C, E, F, G). ECP levels were signiÀ cantly 
increased in IS at 7 hours and 24 hours after ABPT (baseline, 
96.4 [85.5] +g/mL; 7 hours, 380.9 [634.5] +g/mL; 24 hours, 
1520.8 [2126.5] +g/mL) (Figure 2D).
Correlation Analysis of YKL-40 Levels and Other 
Variables in Induced Sputum
Eosinophil count and ECP levels were positively correlated 
with YKL-40 levels in IS (l=0.431, P=.006 for eosinophil 
count; l=0.576, P<.001 for ECP levels) (Figure 3). IL-5 levels 
and other inÁ ammatory cell counts showed no signiÀ cant 
correlation (Table 2).
 
Discussion
Chitin, which consists of N-acetylglucosamine polymers, 
is the second most abundant polysaccharide in nature. It is an 
important component of the cell wall of fungi, the exoskeleton 
of shellÀ sh and insects, and the sheath of nematodes [23]. 
Thus, human beings must have chitinase to protect their bodies 
from many kinds of pathogens containing chitin. Chitinase 
is a highly conserved endogenous enzyme found in insects, 
mammals, and many other organisms. The 2 active chitinases 
in humans, acidic mammalian chitinase and chitotriosidase, 
both have enzymatic activity for the degradation of chitin [23].
YKL-40 is known as a chitinase-like protein because it 
can bind to chitin but is unable to degrade it. Associations 
between YKL-40 and allergic diseases have been reported. 
Chupp et al [15] described a positive correlation between 
elevated serum YKL-40 levels and asthma severity, and the 
same group also reported that a genetic variation of the CHI3L1 
gene encoding YKL-40 was signiÀ cantly associated with serum 
YKL-40 levels and asthma susceptibility [24]. Furthermore, a 
single nucleotide polymorphism in the promoter region of the 
CHI3L1 gene has been associated with the atopic phenotype 
in children [25].
In this study, we observed an increment in YKL-40 levels in 
IS but not in serum at 24 hours after ABPT. The main cell sources 
of YKL-40 are bronchial epithelial cells, macrophages [26], and 
neutrophils [27]. ABPT is used to evaluate allergen-induced 
inÁ ammation in the laboratory. Like other insects and spiders, 
house dust mites contain chitin in their exoskeleton. However, 
YKL-40 elevation in IS might be an independent response to 
chitin, as chitin-free allergens also promote YKL-40 elevation 
in BAL Á uid after administration of the segmental bronchial 
challenge test [28].
Our results strongly suggest that allergen exposure 
may rapidly induce YKL-40 secretion from epithelial cells, 
macrophages, and other cells. The same pattern of increase 
observed for YKL-40 was also observed for IL-5 and ECP in 
IS, suggesting that YKL-40 may increase allergic eosinophilic 
inÁ ammation by inducing the accumulation and activation of 
local dendritic cells and reducing apoptosis of TH2 cells [16]. 
In this study, we used dithiothreitol for mucolysis of IS and 
therefore cannot exclude the possibility that this may have 
affected the measurement of cytokines by ELISA. IL-13 plays 
a critical role in relation to YKL-40 as it can induce YKL-40 
expression from epithelial cells and macrophages, and IL-13-
induced À brosis may be mediated by YKL-40 [29]. Further 
studies are needed to better understand the relationship between 
YKL-40 and allergic inÁ ammation (exacerbated by allergens, 
viruses, smoking, or pollution) and tissue remodeling. 
Our results are not consistent with those of Kuepper 
et al [28], who reported that YKL-40 levels in BAL Á uid 
were markedly increased 24 hours but not 10 minutes after 
segmental allergen challenge. In the present study, we also 
measured YKL-40 in serum but did not À nd any changes in 
YKL-40 levels after ABPT, thus, diminishing the possibility of 
using serum YKL-40 as a biomarker for uncontrolled asthma. 
In contrast to our results, Kuepper et al reported that YKL-
40 in serum was deÀ nitely increased 24 hours after allergen 
challenge, and other investigators have also reported that 
serum YKL-40 levels are higher in exacerbated asthma [30] 
and severe asthma [15]. However, contradictory results have 
also been reported [31]. 
The present study has limitations. First, we did not 
check YKL-40 levels in serum or IS after more than 24 
hours following ABPT. Second, long-lasting uncontrolled 
inÁ ammation can induce the persistent release of YKL-40 
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Table 2. Correlation Analysis of YKL-40 and Other Variables in Induced Sputum
   ECP IL-5 Macrophages Neutrophils Eosinophils
                                     
Correlation coefÀ cient (rho) 0.576 0.304 -0.031 0.245 0.431
P value <.001 .060 .850 .132 .006
Abbreviations: ECP, eosinophil cationic protein; IL, interleukin
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from bronchial epithelial cells, which could affect serum levels 
of YKL-40. ABPT is a good model for studying allergen-
induced allergic inÁ ammation. However, viral infection and 
pollution, in addition to allergens, are also equally important 
aggravating and/or etiologic factors in real-life asthma. Thus, 
ABPT does not sufÀ ciently reÁ ect real clinical situations of 
asthma exacerbation. Some investigators have studied sputum 
YKL-40 levels in asthma and COPD patients and shown that 
YKL-40 and chitinase are increased in COPD patients but not 
in asthmatics compared to healthy controls [11,32]. Therefore, 
whether or not YKL-40 is clinically related to the pathogenesis 
of asthma remains to be elucidated. 
In conclusion, YKL-40 levels in IS increased during the 
early phase of allergic inÁ ammation induced by allergen 
exposure. This À nding suggests that YKL-40 may play an 
important role in the initiation of allergic inÁ ammation and 
that it may be useful as an acute phase biomarker in allergen-
induced asthma exacerbations.
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